You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-Cyclin D1 antibody [CD1.1] (ab6152)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-Cyclin D1 antibody [CD1.1]
See all Cyclin D1 products (18) ...

Description

Mouse monoclonal [CD1.1] to Cyclin D1

Specificity

Recognises Cyclin D1

Tested applications

IHC-P, IHC-Fr, Flow Cyt, WB, IP, ELISAmore details

Cross reactivity

Reacts with

Mouse, Rat, Human

Immunogen

Full length protein (Human).

Positive control

Small intestine, colon

Properties

Form

Liquid

Storage instructions

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze / thaw cycles.

Storage buffer

Tris - glycine, 0.1% sodium azide

Concentration

Concentration information loading...

Purity

IgG fraction

Clonality

Monoclonal

Clone number

CD1.1

Myeloma

Sp2

Isotype

IgG1

Applications

Show applications key

Our Abpromise guarantee covers the use of ab6152 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Target

Function

Essential for the control of the cell cycle at the G1/S (start) transition.

Involvement in disease

Note=A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.
Note=A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.
Defects in CCND1 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.

Sequence similarities

Belongs to the cyclin family. Cyclin D subfamily.

Post-translational
modifications

Phosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.
Ubiquitinated, primarily as 'Lys-48'-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB (By similarity). Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to stabilize it.

Cellular localization

Nucleus.

Target information above from: UniProt accessionP24385 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • AI327039 antibody
  • B cell ccl/lymphoma 1 antibody
  • B cell CLL/lymphoma 1 antibody
  • B cell leukemia 1 antibody
  • B cell leukemia 1 antibody
  • B cell lymphoma 1 protein antibody
  • B-cell lymphoma 1 protein antibody
  • BCL 1 antibody
  • BCL-1 antibody
  • BCL-1 oncogene antibody
  • BCL1 antibody
  • BCL1 oncogene antibody
  • CCND 1 antibody
  • CCND1 antibody
  • CCND1 protein antibody
  • CCND1/FSTL3 fusion gene, included antibody
  • CCND1/IGHG1 fusion gene antibody
  • CCND1/IGHG1 fusion gene, included antibody
  • CCND1/IGLC1 fusion gene, included antibody
  • CCND1/PTH fusion gene, included antibody
  • CCND1_HUMAN antibody
  • cD1 antibody
  • Cyl 1 antibody
  • D11S287E antibody
  • G1/S specific cyclin D1 antibody
  • G1/S-specific cyclin-D1 antibody
  • Parathyroid adenomatosis 1 antibody
  • PRAD1 antibody
  • PRAD1 oncogene antibody
  • U21B31 antibody
see all

References for Anti-Cyclin D1 antibody [CD1.1] (ab6152)

This product has been referenced in:

  • Wei Wet al. Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. Mol Cancer 10:16 (2011). WB, IHC; Human.Read more (PubMed: 21314951) »
  • Bimpaki EIet al. Abnormalities of cAMP signaling are present in adrenocortical lesions associated with ACTH-independent Cushing syndrome despite the absence of mutations in known genes. Eur J Endocrinol 161:153-61 (2009).Read more (PubMed: 19429701) »

See all 10 publications for this product

Publishing research using ab6152? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"